Journal article : Review
Viral vector vaccines
- Abstract:
- Over the past two years, the SARS-CoV-2 pandemic has highlighted the impact that emerging pathogens can have on global health. The development of new and effective vaccine technologies is vital in the fight against such threats. Viral vectors are a relatively new vaccine platform that relies on recombinant viruses to deliver selected immunogens into the host. In response to the SARS-CoV-2 pandemic, the development and subsequent rollout of adenoviral vector vaccines has shown the utility, impact, scalability and efficacy of this platform. Shown to elicit strong cellular and humoral immune responses in diverse populations, these vaccine vectors will be an important approach against infectious diseases in the future.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 744.8KB, Terms of use)
-
- Publisher copy:
- 10.1016/j.coi.2022.102210
Authors
- Publisher:
- Elseveir
- Journal:
- Current Opinion in Immunology More from this journal
- Volume:
- 77
- Article number:
- 102210
- Publication date:
- 2022-05-25
- Acceptance date:
- 2022-04-15
- DOI:
- EISSN:
-
1879-0372
- ISSN:
-
0952-7915
- Pmid:
-
35643023
- Language:
-
English
- Keywords:
- Subtype:
-
Review
- Pubs id:
-
1263718
- Local pid:
-
pubs:1263718
- Deposit date:
-
2022-08-09
- ARK identifier:
Terms of use
- Copyright date:
- 2022
- Rights statement:
- © 2022 Published by Elsevier Ltd.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.coi.2022.102210
If you are the owner of this record, you can report an update to it here: Report update to this record